Search / 326 results found Showing: 1-10 of 326
We are in a battle the likes of which the world has not seen for a century. Over 36 million Americans – more than 1 in 10 people in the United States – have been infected with Covid-19 and over 200 million people worldwide. New and more infectious variants have brought U.S. infection rates to their second-highest levels of the pandemic.
(The Center Square) – After repeatedly warning of the potential for a winter surge of COVID-19 in recent weeks, Gov. Gavin Newsom told reporters Monday that California is starting to see some improvements in case rates and hospitalizations heading into the holiday season.
SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that data from the Phase 1 study of DNX-2401 in diffuse intrinsic pontine glioma (DIPG) was presented in an oral presentation at the 26th Annual Meeting and Education Day of the Society for Neuro-oncology (SNO), which was held from November 18-21, 2021 in Boston, MA. DNX-2401 is an adenovirus-based immunotherapy that is engineered to selectively kill tumor cells and trigger a robust anti-tumor immune response. It has received FDA Fast Track and Rare Pediatric Disease designations for DIPG.
SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been validated by Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services. This novel test is highly sensitive and specific, and can quantify a patient's SARS-CoV-2 viral load to determine the active infection level.
SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- InsightRX, which provides a cloud-based precision dosing platform to help guide treatment decisions, today announced that Memorial Sloan Kettering Cancer Center (MSK) has implemented its precision dosing platform to tailor dosing of certain chemotherapy and immunosuppressive drugs used in the administration of stem cell transplants to patients with hematological malignancies and other cancers.
Dr. Jennifer Clark said hospitals could encounter another “nightmare winter” if influenza hits hard: “Given the fact that we did not have a flu season last year, we’re at risk for having the classic twindemic they’ve been talking about."
HUNTINGTON BREACH, Calif., Nov. 22, 2021 /PRNewswire/ -- The Institute for Molecular Medicine (IMM), a non-profit research organization established in 1996 with the goal of understanding, preventing, and curing chronic diseases, including neurodegenerative disorders, today announced that it has been awarded an additional $3 million to the previously awarded $4.7 million grant from the National Institutes of Aging (NIA) of the NIH. The funding will support the manufacturing of a first-of-its-kind clinical cGMP grade dual vaccine, Duvax, that targets both pathological hallmarks of Alzheimer's disease (AD), amyloid beta plaques (Aβ) and neurofibrillary tangles (tau).
SAN FRANCISCO and SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced first interim analysis results of the randomized, double-blinded, multi-center Phase 3 ORIENT-31 study conducted in China evaluating sintilimab and anti-VEGF antibody combination therapy (i.e., sintilimab plus BYVASDA® [bevacizumab biosimilar injection] combined with chemotherapy [pemetrexed and cisplatin]) in patients with EGFR-mutated non-squamous non-small cell lung-cancer (nsqNSCLC) who progressed after EGFR-TKI therapy in an oral presentation at the ESMO (European Society for Medical Oncology) Virtual Plenary: November 2021 (Abstract #300).
Globalization has been mostly plusses, but the rapid spread of the coronavirus last year has illustrated an enormous minus: humans are not the only species that’s hyperconnected anymore, viruses are too. This is going to be an ongoing war between humans and viruses, and Americans need to find the best practices for the future.
WESTLAKE VILLAGE, Calif., Nov. 18, 2021 /PRNewswire/ -- Genelux Corporation, a clinical-stage immunotherapy company, today announced an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health, a biotechnology company advancing its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine. V-VET1is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis).